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Abstract
There is good evidence that poor sleep quality increases risk of painful temporomandibular 
disorder (TMD). However little is known about the course of sleep quality in the months preceding 
TMD onset, and whether the relationship is mediated by heightened sensitivity to pain. The 
Pittsburgh Sleep Quality Index was administered at enrollment into the OPPERA prospective 
cohort study. Thereafter the Sleep Quality Numeric Rating Scale was administered every three 
months to 2,453 participants. Sensitivity to experimental pressure pain and pinprick pain stimuli 
was measured at baseline and repeated during follow-up of incident TMD cases (n=220) and 
matched TMD-free controls (n=193). Subjective sleep quality deteriorated progressively, but only 
in those who subsequently developed TMD. A Cox proportional hazards model showed that risk 
of TMD was greater among participants whose sleep quality worsened during follow-up (adjusted 
hazard ratio=1.73, 95% confidence limits: 1.29, 2.32). This association was independent of 
baseline measures of sleep quality, psychological stress, somatic awareness, comorbid conditions, 
non-pain facial symptoms and demographics. Poor baseline sleep quality was not significantly 
associated with baseline pain sensitivity or with subsequent change in pain sensitivity. 
Furthermore the relationship between sleep quality and TMD incidence was not mediated via 
baseline pain sensitivity nor change in pain sensitivity.
Keywords
Epidemiology; musculoskeletal pain; pain perception; psychological stress; sleep quality
INTRODUCTION
Adults with chronic pain report a sleep debt of 42-minutes per night, exceeding the 14-
minute sleep debt of adults with acute pain and the absence of sleep debt in adults with no 
pain.27 In addition, only 37% of adults with chronic pain rate their sleep quality as good or 
very good, compared to 65% of adults with no pain.27 These nationally representative 
findings of the 2015 Sleep in America poll add a population insight to experimental and 
clinical evidence that pain worsens sleep, likely via cortical arousal which interferes with 
sleep onset and sleep maintenance.6, 22
Just as pain disturbs sleep, sleep disturbance increases sensitivity to experimental 
pain,10, 19, 26, 29, 38 revealing the bidirectional nature of this relationship. In fact, napping 14 
or extending sleep time 33 can reverse elevated sensitivity to pain induced by sleep 
deprivation. Determining the predominant direction of the sleep and pain relationship was 
the focus of three comprehensive reviews. These reviews examined longitudinal studies 
published before 2005,39 experimental studies published before 200721 and longitudinal and 
experimental studies published from 2006 to 2012.16 It is now clear from the more nuanced 
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temporal analyses that sleep disturbances are stronger, more reliable predictors of pain 
development than are pain complaints predictors of sleep disturbance.16
An association between sleep disturbance and painful temporomandibular disorder (TMD) is 
well established. Sleep fragmentation, respiratory effort related arousals, 11 insomnia, 31, 40 
and poor sleep quality 36 are each more common in people with TMD than pain-free 
controls. The limitation of all but one 31 of these studies was reliance on cross-sectional 
data. One contribution of the Orofacial Pain: Prospective Evaluation and Risk Assessment 
(OPPERA) prospective cohort study was to show that baseline assessments of obstructive 
sleep apnea symptoms34 and poor subjective sleep quality 35 predicted development of first-
onset painful TMD among adults with no lifetime history of TMD.
Most cross-sectional analyses of variability in pain thresholds show that chronic TMD cases 
have lower pain thresholds than pain-free controls for a wide range of experimentally evoked 
noxious pain stimuli, both in the orofacial region and in extra-cranial sites.18, 23, 24, 40 Hence 
it is reasonable to expect that individuals with poor sleep quality may lower pain thresholds 
and that this effect may mediate the relationship between poor sleep quality and risk of 
developing TMD.
What has yet to be characterized is the longitudinal trajectory of sleep quality prior to 
development of painful TMD. It is not clear whether sleep quality is stable, fluctuating or 
worsening in the months prior to first-onset TMD. Consequently our study had two aims. 
First we examined the temporal dynamics of sleep quality in a cohort of initially TMD-free 
adults followed over time, comparing sleep quality trajectories of incident TMD cases with 
those of matched TMD-free controls in the cohort. We evaluated the contribution of sleep 
quality trajectories to risk of developing first-onset TMD. Second we estimated the potential 
mediation of heightened sensitivity to experimental pain in the pathway between poor sleep 
quality and TMD development. We hypothesized that poor sleep quality has a hyperalgesic 
effect which, in turn, increases risk of developing TMD.
METHODS AND MATERIALS
Institutional review boards at each study site approved the study procedures, and signed, 
informed consent was obtained from each participant. This article complies with 
recommendations made for the Reporting of Observational Studies in Epidemiology 
(STROBE).42
Study Design
This study utilized two studies designs, both of which drew on the OPPERA study. 
OPPERA is an acronym for Orofacial Pain: Prospective Evaluation and Risk Assessment 
(OPPERA) project. Essentially OPPERA is a series of community-based epidemiologic 
studies designed to characterize the etiology and persistence of painful TMD. This analysis 
draws upon two of OPPERA's studies. These are the prospective cohort study and its nested 
case control study (described below). The advantage of the nested case control study is that 
it combines the efficiency and comparison group of a conventional case control study. 
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Meanwhile the strength of the prospective cohort study is its longitudinal design in which 
exposure is ascertained prior to TMD onset.
Setting, Study Participants and Enrollment
OPPERA recruited community-based volunteers into its prospective cohort between May 
2006 and November 2008. Its four study sites are located at Baltimore, Maryland; Buffalo, 
New York; Chapel Hill, North Carolina; and Gainesville, Florida. Initially, potential 
participants were screened for eligibility. Those who were aged between 18 to 44 years, with 
no significant history of TMD symptoms, no significant medical illnesses or recent history 
of facial injury or surgery, not pregnant or nursing, ≤4 headaches per month within the 
preceding 3 months, not receiving orthodontic treatment, never diagnosed with TMD, and no 
use of a night-guard occlusal splint were invited to come to a clinic appointment. There they 
were clinically examined using Research Diagnostic Criteria for TMD (RDC/TMD).12 A 
total of 3,263 were confirmed as TMD-free were enrolled and followed for up to 5.2 years 
(median follow-up = 2.8-years).
Baseline Assessment of Subjective Sleep Quality and Experimental Pain Sensitivity
At enrollment, OPPERA participants completed standardized questionnaires with well-
established psychometric properties. Habitual sleep quality and sleep disturbance in the past 
month was assessed using the 19-item Pittsburgh Sleep Quality Index (PSQI).7 The PSQI 
has seven subscales that assess subjective sleep quality, sleep latency, sleep duration, sleep 
efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Each 
subscale is weighted equally, scored from 0–3, summing to a global score (range, 0–21). 
Higher scores denote worse sleep quality and a global score greater than 5 has diagnostic 
sensitivity of 89.6% and specificity of 86.5% in distinguishing poor from good sleep.7 In 
people who have TMD, the PSQI is a unidimensional construct. 32 Hence, in this analysis 
we used the PSQI's single global score.
Methods for quantitative sensory testing (QST) of thermal pain, pressure pain and 
mechanical pain in OPPERA have been described in detail.18 In OPPERA, QST assessed 
pressure pain, mechanical cutaneous (pricking) pain, and heat pain. Of these three sensory 
domains, pressure pain thresholds (PPTs) were most strongly associated with chronic 
TMD.18 PPTs were assessed bilaterally at the center of the temporalis muscle; the center of 
the masseter muscle; the temporomandibular joint; the center of the trapezius muscle; and 
the lateral epicondyle. PPT was determined using a pressure algometer and recorded in 
kilopascals (kPa).
Mechanical cutaneous (pinprick) pain sensitivity was assessed using weighted probes of 
0.2mm diameter that exerted a force of 512 mN applied to the dorsum of digits 2 to 4. 
Participants rated pain using a 0–100 numeric rating scale reported immediately following a 
series of 10 stimuli (wind-up protocol) and 15 seconds later. This current analysis was 
confined to assessment of PPTs at the trapezius muscle site. Being anatomically remote from 
the temporomandibular joint region, sensitivity to experimental pain of the trapezius muscle 
is unlikely to be conflated with TMD pain in cases, and more likely to point to a generalized 
upregulation of nociceptive processing. The study reports findings for sensitivity to 
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experimental pain and change from baseline in experimental pain sensitivity for pressure 
pain sensitivity and mechanical cutaneous pain. We do not report results for thermal pain in 
this study because there was a larger number of missing observations for thermal pain 
measures.
Follow-up Visit for Ascertainment of Incident TMD and Selection of Matched Control 
Subjects
During follow-up study participants completed the Quarterly Health Update questionnaire 
every three months. Its purpose was to screen for TMD pain symptoms. Follow-up 
continued in this way either until clinically-determined TMD developed, the study ended (in 
May 2011), or until participants were lost to follow-up. Participants who had experienced 
orofacial pain symptoms were invited to a follow-up clinic visit. At that appointed the 
RDC/TMD examination was repeated to determine the presence or absence of TMD. Some 
TMD incident cases may have had joint-meniscus problems, although those conditions were 
not classified by examiners. As incident cases were identified, one control participant at 
random was matched to the incident case. Controls were cohort members who had not 
developed TMD. They were matched to the case by study site, time in study, and sex. The 
study participant selected as matched control was likewise invited to a follow-up clinic visit 
where examiners verified absence of clinical TMD. Experimental pain procedures were 
repeated at the follow-up visit, both for incident cases and matched controls. The median 
period between enrollment and the second examination was 17 months (interquartile range = 
10–26 months).
Assessment of Subjective Sleep Quality during Observation Period
The Quarterly Health Update also monitored subjective sleep quality using the Sleep Quality 
Numeric Rating Scale (NRS). Participants were instructed to rate their sleep quality over the 
preceding three months. An anchor value of 0 represented “worst sleep imaginable” while 
the anchor value of 10 represented “best sleep imaginable”. The Sleep Quality NRS is brief, 
simple to administer, and easy to understand and complete.25 Its psychometric properties of 
reproducibility, convergent validity, and responsiveness to treatment are established in 
individuals with chronic pain in two independent clinical trials.8, 25 The Sleep Quality NRS 
is also sensitive to detecting change in response to intervention. This was demonstrated in a 
review of 12 clinical trials of pregabalin versus placebo to treat pain and sleep disturbance in 
fibromyalgia patients. Improvements in sleep quality—assessed with the Sleep Quality NRS
—were observed in 11 of the 12 trials in as little as one or two days of treatment.3 In this 
analysis, the Sleep Quality NRS values were reverse coded for directional consistency with 
the PSQI in which higher scores denote worse sleep quality.
The number of completed Quarterly Health Updates completed per person varied 
accordingly to the length of time they were enrolled in the study. We standardized these 
reporting periods in the following way. The first quarter refers to the three months following 
enrollment into the OPPERA cohort. The final quarter refers to the three months preceding 
the follow-up visit.
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The penultimate quarter refers to the three months preceding the final quarter, and the 
intermediate quarters are the pooled periods that fall between the first and penultimate 
quarters.
Covariates
In addition to study site, age, sex, race and ethnicity, multivariable analysis adjusted for the 
four strongest predictors of incident TMD in OPPERA 5 to eliminate their potential 
confounding effects. These were: non-painful facial symptoms (stiffness or tightness, 
cramping, fatigue, pressure, soreness or tenderness, ache or dull ache); score for the 
Pennebaker Inventory of Limbic Languidness (PILL);30 score for the Perceived Stress 
Scale; 9 and a checklist of 20 comorbid health conditions, which included psychological 
conditions, painful conditions, and sleep disorders.
Sample size determination
The planned sample size of the OPPERA prospective cohort study (N=3,200) was based on 
an expected yield 196 first-onset TMD cases. This sample size would have 80% statistical 
power to detect risk ratios of at least 1.8 for risk predictors with as few as 15% of people in 
the high-risk category.4 In fact, the actual number of first-onset cases (n=260) slightly 
exceeded the estimated number of 196, providing adequate power to detect an effect of poor 
sleep quality, even after adjustment for potential confounding (adjusted hazard ratio for sleep 
quality during follow-up=1.73, 95% confidence limits: 1.29, 2.32).
Statistical analysis
Person-years of follow-up were calculated from enrollment until time of clinical 
ascertainment of incident TMD, loss to follow-up, or the end of the follow-up period in May 
2011. The main predictor was subjective sleep quality, measured at enrollment with the 
PSQI and thereafter with the Sleep Quality NRS. Adjusted means for sleep quality were 
calculated from a generalized estimating equation regression model in which the Sleep 
Quality NRS (range 0-10, higher scores denote worse sleep quality) was the dependent 
variable. Predictor variables were time of data collection (4 reporting periods), and TMD 
incident case classification (2 categories) and their 2-way interaction. Estimates were 
adjusted for study site, sex, age in years and race/ethnicity. In addition to computing mean 
values of it continuous measure, the Sleep Quality NRS was used dichotomized at its 
median value of 6, interpreted as ratings of 0-6 representing good sleep quality and ratings 
of >6 representing poor sleep quality.
Cox models with a time-varying covariate were used to evaluate the contribution of 
temporally-varying subjective sleep quality to risk of developing first-onset TMD. The time-
varying Sleep Quality NRS variable was “lagged” by selecting the follow-up questionnaire 
completed in the quarter prior to the quarter used when calculating the partial likelihood. 
This lagged method avoided the problem of reverse causation by using Sleep Quality NRS 
reported in the questionnaire that preceded the concurrent quarter. Because all participants, 
including incident cases, were TMD-free in the lagged quarter, time-varying Sleep Quality 
NRS could not be influenced by TMD because TMD had not yet developed, even in incident 
cases.
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An initial Cox model included the time-constant covariate of PSQI sleep quality reported at 
baseline, together with demographics and study site. A second model additionally adjusted 
for the other covariates.
The third model then determined the contribution of a time-varying sleep quality over time 
during follow-up, which we expected to be a more informative indicator of risk than a single 
baseline measurement.
The likelihood ratio test statistic measured overall fit for each model, and hazard ratios with 
corresponding 95% confidence intervals (95% CI) were estimated for each predictor 
variable. To address potential problems of residual confounding and information bias created 
by dichotomizing continuous sleep quality variables, an alternative to Model 3 used PSQI 
and NRS measures as continuous variables, each divided by its respective standard 
deviation. Resulting hazard ratios represent the effects of a 1-standard-deviation increase in 
each of the predictor variables.
To investigate potential mediation of the relationship between sleep quality and incident 
TMD by experimental pain sensitivity, we proceeded to decompose the total effect into the 
natural direct (effects not mediated through experimental pain sensitivity) and the natural 
indirect effect using the counterfactual based approach to mediation analysis that allows for 
non-linear dependencies. 43 Two potential mediators were considered: pressure pain 
threshold and average pinprick pain. Each of these potential mediators was then modeled 
separately in 2 ways, first as the corresponding baseline measure and second as change from 
baseline measure i.e. difference between follow-up and baseline score. To control for 
confounding, we created inverse probability of exposure (sleep quality) and mediator 
(experimental pain sensitivity and change from baseline pain sensitivity) weights and fitted 
an inverse probability weighted Cox proportional hazards regression using robust variance 
estimation to obtain hazard ratios and 95% CI for the intended effects. A detailed description 
of the mediation analysis methods is available in the online appendix.
RESULTS
A total of 2,453 OPPERA cohort participants had valid PSQI data at enrollment and 
completed at least two follow-up Quarterly Health Update questionnaires over the median 
2.8-years of follow-up. TMD developed at a rate of 3.0% of people per annum (Table 1).
The rate of TMD incidence was twice as high in participants whose baseline subjective sleep 
quality was poor (4.6%, 95% CL: 3.8, 5.7) rather than good (2.1%, 95% CL: 1.7, 2.5). Mean 
baseline sleep quality (PSQI score) did not differ significantly between men and women. 
Mean PSQI scores exceeded 5—the threshold for poor sleep quality—for African 
Americans, participants with heightened perceived stress or somatic awareness, and 
participants with non-pain facial symptoms or comorbid conditions. Of note, baseline sleep 
quality was not associated with baseline measures of trapezius pressure pain threshold or 
ratings of pinprick pain (Table 1).
During the observation period, the mean level of impairment in sleep quality increased from 
the first quarter by 11% on average among those who became incident cases (p=0.001). By 
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contrast, no significant change in sleep quality was observed for matched controls (3%, 
p=0.5) (Appendix Table 1). At the final quarter that precipitated the follow-up visit in which 
TMD incidence was determined, the magnitude of difference in sleep quality between 
incident cases and matched controls was 17%.
Depicted graphically (Figure 1), sleep quality measured at both the penultimate and final 
quarters was significantly worse than the baseline level for TMD incident cases while 
remaining unchanged for matched controls.
In multivariable Cox proportional hazards analysis that adjusted for study site and 
demographic characteristics (Table 2, Model 1), baseline poor sleep quality (PSQI score >5) 
was associated with a significantly increased risk of TMD incidence (adjusted HR=2.04, 
95% CL: 1.55, 2.70).
Further adjustment for perceived stress, somatic awareness, comorbid conditions and non-
pain facial symptoms attenuated the degree of association by 32% (HR=1.39, 95% CL: 1.02, 
1.90), but baseline poor sleep quality remained a significant predictor of TMD (Table 2, 
model 2). In the presence of all of these factors, the dichotomized time-varying sleep quality 
rating was an independent risk factor (Table 2, model 3).
The risk of developing TMD was 73% higher (HR=1.73: 95% CL: 1.29, 2.32) in participants 
with poor sleep quality (numeric rating >6) during the observation period compared to 
participants with a sleep quality rating in the range of 0 to 6. Findings were analogous using 
continuous measures of sleep quality (Appendix Table 3). The likelihood ratio test statistic 
increased across successive models, indicating better model fit as variables were added.
At baseline, there was no statistically significant relationship between sleep quality and the 
QST measures, either in TMD cases or matched controls (Appendix Table 2). Neither did 
QST measures modify the relationship between baseline sleep quality and TMD status. 
Moreover the magnitude of change in QST measures from baseline to follow-up did not 
differ between TMD incident cases and matched controls.
The results of our mediation analysis suggest that the relationship between sleep quality and 
incident TMD is not mediated by pressure pain threshold (Table 3) or average pinprick pain 
(appendix table 3). While the estimates of the direct effect were stronger when baseline 
experimental pain measures were modeled as mediators as opposed to change from the 
baseline measures, this was not the case for the respective indirect effects, which were all 
estimated as null (Table 3 and appendix Table 2).
After taking account of the major risk factors for TMD, the risk of developing TMD 
remained elevated 73% in poor sleepers compared to good sleepers.
DISCUSSION
In this cohort of initially TMD-free adults, subjective sleep quality deteriorated 
progressively prior to the onset of pain symptoms in people who developed painful TMD. 
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By contrast, there was no change in sleep quality during follow-up among those who 
remained TMD-free.
Participants with baseline poor sleep quality developed first-onset TMD at twice the rate as 
participants with good sleep quality (demographically adjusted HR 2.04 95% CI: 1.55, 
2.70). The magnitude of this effect size has considerable importance to clinical practice, 
given that sleep quality is amenable to intervention. The implication is that, if poor sleep 
quality were to be mitigated in these individuals, their rate of TMD incidence would be 
halved. After taking account of the major risk factors for TMD, the risk of developing TMD 
remained elevated 73%, in poor sleepers compared to good sleepers.
The effect of deteriorating sleep quality on TMD onset was independent of baseline sleep 
quality and other baseline measures that were among the strongest predictors of TMD in 
OPPERA. These were somatic awareness, perceived stress, comorbid health conditions and 
non-painful facial symptoms. We found no evidence that poor sleep quality was associated 
with sensitivity to experimental pain stimuli. Moreover, we found no evidence that the effect 
of poor sleep quality on risk of TMD was mediated via sensitivity to experimental pain.
These findings build upon our earlier OPPERA finding that poor sleep quality at baseline 
predicted increased risk of developing TMD. 35 First we monitored sleep quality 
longitudinally over a median 2.8 year follow-up and found a downward trajectory before the 
onset and clinical confirmation of TMD. Second we contrasted this dynamic trajectory to the 
stable trajectory in a comparison group that remained TMD-free. Third we showed that the 
effect of poor sleep quality on TMD onset was not mediated by pain sensitivity. Our analytic 
Cox models, including the mediation models, controlled for the potential confounding of 
perceived stress. This was necessary as stress is associated with primary insomnia17 and 
experimentally-evoked pain sensitivity 23 and predicts the subsequent development of 
TMD.15
Our findings permit interpretation that poor sleep quality is not merely a surrogate marker of 
psychological stress. A large number of studies have shown that baseline sleep problems 
increase risk for development of widespread musculoskeletal pain. However we believe this 
to be the first population-based cohort to have monitored sleep quality every few months as a 
risk factor for pain onset.
Our a priori expectation that worsening subjective sleep quality would predict increased 
sensitivity to experimental pain was based on knowledge that disruptive sleep enhances pain 
perception,20 predicts the number of tender points26, and disturbs pain inhibiting 
processing 38 including among adults with chronic TMD.13 However, inconsistent findings 
are reported. For example, interruption in delta wave sleep over three consecutive nights 
predicted widespread pain, but did not predict reduced pain thresholds. 28 One possibility is 
that sleep deprivation modulates nociception differently at different stages of sleep. The 
effects on pain of chronic sleep restriction and sleep fragmentation (such as the arousals 
induced by obstructive sleep apnea) have received considerably less research attention than 
total sleep deprivation which is a deprivation of all sleep stages, including rapid eye 
movement sleep.
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It is important to note that OPPERA's longitudinal analysis only weakly supported the 
premise that elevated sensitivity to pain predicted TMD onset. The best prediction was 
observed when change in pressure pain thresholds was measured from enrollment to onset 
TMD,37 which is why we used change scores in our mediation analysis, not simply baseline 
scores of QST. Yet even the change scores did not mediate the effect of sleep quality on 
TMD.
For the mediation analysis, we made untestable assumptions that the variables used in 
creating the inverse probability weights were sufficient to adjust for confounding between: 
sleep quality and TMD onset; sleep quality and pain sensitivity; and pain sensitivity and 
TMD onset. We also assumed that there were no confounders of pain sensitivity and TMD 
onset affected by sleep quality. We also point out that mediation was explored in only a 
subset of the OPPERA cohort—the nested case control participants—so our power to detect 
an association between sleep quality and TMD onset was lowered somewhat, although 
importantly the number of incident cases in the nested case control study was no less than in 
the prospective cohort study.
At no time during the study was sleep assessed clinically. Neither was objective information 
collected on sleep disorders such as insomnia, periodic limb movement, and sleep-
disordered breathing. In this study sleep quality was assessed differently at baseline (PSQI) 
than during follow-up (Sleep Quality NRS), which precluded evaluation of change in sleep 
quality in the first post-enrollment quarter. This probably attenuated the magnitude of sleep 
quality deterioration in people who later developed TMD, and hence our estimates are 
conservative.
Use of the sleep quality NRS is mostly restricted to clinical trials treating fibromyalgia 
patients with pregabalin, and its psychometric properties have been validated in those 
settings.8, 25 It has also been applied to explore the impact of sleep disorders on postural 
stability1, 2 but few other studies are reported. Despite its limited application to sleep, the 
NRS is a widely used methodology that has long been well accepted in as a measure of pain 
intensity. It is simple to use and requires no training. For these reasons, there is no reason to 
think that the NRS is not a reliable and responsive measure of other subjective phenomenon, 
such as sleep quality.
Self-reported sleep quality is only modestly correlated with objective assessment obtained 
by polysomnogram (PSG). Hence discordant findings from the two modalities are common. 
For example, menopausal women in the Wisconsin Sleep Cohort Study reported worse sleep 
quality than their premenopausal peers, yet PSG found that postmenopausal women had 
more deep sleep and significantly longer total sleep time than the premenopausal women.44 
In the Sleep Heart Health Study, older women had good subjective sleep quality, yet poor 
PSG-determined sleep quality, while the reverse was true for older men.41 Therefore we 
point out that subjective and objective sleep quality should not be viewed as equivalent 
constructs.
This leaves open the possibility that objectively-measured aspects of sleep might likewise 
affect risk of TMD, and through pathways that are mediated via experimental pain 
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sensitivity. Objectively evaluated sleep quality parameters would offer physiological validity 
to ratings of habitual sleep quality and enhance our understanding of this complex 
relationship.
A major strength of this study was the repeated prospective ascertainment of sleep quality 
before the onset of TMD, the measurement of individual change in sleep quality, and the 
modeling of these correlated time-varying covariates in Cox models. Another strength was 
the measurement of QST measures at enrollment and when incident TMD was confirmed. A 
third strength was the utilization of a nested case control design, which capitalized on the 
longitudinal design of the cohort and provided a matched control. Finally, the formal 
mediation analysis is a powerful technique with longitudinal data to understand causal 
pathways between an exposure and an outcome.
Our findings point to directions for future research. Psychometricians will continue to test 
the properties of the sleep quality NRS. The OPPERA investigators are interested in 
determining whether sleep quality may itself be a mediator of the relationship between 
psychological stress and TMD incidence. Another question of particular interest to clinicians 
is whether interventions that improve sleep quality prevent the onset of pain in high-risk 
groups, and mitigate pain in people with existing pain disorders.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Appendix
Statistical Methods-Mediation analysis
To investigate potential mediation of the sleep quality-incident TMD association by 
experimental pain sensitivity, we proceeded to decompose the total effect into the direct 
(effects not mediated through experimental pain sensitivity) and indirect effects. To 
accomplish this, we used the counterfactual based approach to mediation analysis as 
described by Lange and colleagues (Lange et al., 2012). First the exposure (PSQI score) was 
dichotomized and individuals with score >5 were considered as having poor sleep quality. 
We chose pressure pain threshold of the trapezius muscle and average pinprick pain as our 
potential mediators. These potential mediators were modeled separately as baseline pressure 
pain threshold, change from baseline pressure pain threshold, baseline average pinprick pain 
and change from baseline average pinprick pain. And similar to the exposure, we 
dichotomized these variables at the lower tertile of their distribution. Next, we proceeded to 
identify a sufficient set of confounding variables C (study site, age, sex, race/ethnicity, the 
Perceived Stress Scale score, the Pennebaker Inventory of Limbic Languidness (PILL) score, 
Sanders et al. Page 11
J Pain. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
a count of 20 comorbidities, and a count of non-pain facial symptoms) of the exposure-
outcome, exposure mediator and mediator outcome relationships. We then created inverse 
probability (IP) weights separately for the exposure and mediators. The inverse probability 
of exposure weight is the inverse of the predicted probability of the exposure conditional on 
observed covariates C. The purpose of weighting is to create a pseudo-population consisting 
of wi copies of each subject i (Robins et al., 2000), such that a given individual with for 
instance a weight of 6 contributes 6 copies of themselves to the pseudo-population. Thus, in 
this pseudo-population, the exposure is no longer associated with confounders C. In other 
words, the IP of exposure weight controls for confounding by the set of covariates C used in 
constructing it.
In small to moderate sized samples, the inverse probability weights tend to be unstable 
because certain individuals with large weights tend to dominate the estimation (Robins et al., 
2000). Thus we stabilized this weight by substituting in the numerator of the weight, the 
marginal probability of the exposure for the exposed and 1 minus this value for the 
unexposed. The stabilized inverse probability of exposure weight is thus:
Where xi and ci are the actual values of the exposure and covariates for individual i. Next we 
created mediator weights as detailed in Lange et al (Lange et al., 2012) by first constructing 
a new dataset with replicates of each observation in the original dataset twice and creating a 
new variable (xstar) that captures the 2 possible values of the exposure relative to the 
indirect path. For the first replication of each observation, xstar was set to the actual value of 
the exposure (x) and set to the opposite of the actual exposure for the second replicate. We 
then proceeded to create mediator weights that correspond to the direct and indirect paths. 
Specifically, we estimated the following weights:
The numerator of the weight corresponds to covariate and exposure conditional predicted 
probability relative to the indirect path and the denominator is the same but for the direct 
path.
To obtain the final weight, we multiplied the exposure weight by the mediator weight 
 and fitted an inverse probability weighted cox proportional hazards model with 
robust variance estimation to obtain Hazard ratios and 95% CI.
The coefficient β1 for x corresponds to the log hazard estimate of the natural direct effect 
while the coefficient β0 for xstar corresponds to the log hazard estimate of the natural 
indirect effect. A final caveat is that the validity of this method depends on correct 
Sanders et al. Page 12
J Pain. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
specification of both the exposure and mediator weight models. We also assumed that the set 
of confounders used in creating these weights controlled for the exposure-outcome, 
exposure-mediator and mediator-outcome confounding and that there were no exposure 
induced mediator-outcome confounders.
Appendix Table 1
Adjusted(a) Mean Sleep Quality Numeric Rating Scale Scores(b) at Four Time Points in the 
OPPERA Nested Case-Control Study of TMD (N=413)(c)
First quarter Intermediate quarters Penultimate quarter Final quarter
TMD incident cases (n= 220)
    Sleep quality score, mean (SE) 4.34 (0.17) 4.49 (0.16) 4.67 (0.18) 4.83 (0.17)
    % Change relative to first 
quarter
- 3% 8% 11%
    P value for change from first 
quarter
- 0.244 0.032 0.001
Matched controls (n= 193)
    Sleep quality score, mean (SE) 4.00 (0.18) 4.04 (0.15) 3.87 (0.18) 4.12 (0.17)
    % Change relative to first 
quarter
- 1% −3% 3%
    P value for change from first 
quarter
- 0.761 0.464 0.451
Contrast cases versus matched 
controls
    % Difference 9% 11% 21% 17%
    P value for contrast 0.084 0.006 0.000 0.000
(a)Adjusted for study site, sex age in years and race/ethnicity
(b)
Higher mean scores denote worse sleep quality
(c)Selection of TMD cases and matched controls is limited to participants in the nested case-control study who completed 
at least two Quarterly Health Update questionnaires during follow-up
Appendix Table 2
Baseline estimates (mean (standard error (SE))(a) and change from baseline in quantitative 
sensory testing (QST) measures according to sleep quality for incident TMD cases and 
match controls in the OPPERA nested case-control study (n=431)
Baseline sleep quality P
Good (PSQI 0-3) Moderate (PSQI >3-5) Poor (PSQI >5)
Baseline QST measures Mean (SE) Mean (SE) Mean (SE)
    Trapezius pressure 
pain threshold (kPa)
Case 316 (17) 370 (17) 349 (13) 0.3(d)
Matched control 356 (15) 370 (18) 337 (20)
P=0.5(b) P=0.1(c)
    Mean pinprick pain 
rating (0-100) (N=378)
Case 18.0 (2.6) 14.4 (2.7) 17.8 (2.0) 0.9(d)
Matched control 22.4 (2.3) 16.7 (2.7) 20.8 (3.3)
P=0.1(b) P=0.2(c)
    Pinprick post-stimulus 
rating (0-100) (N=377)
Case 2.35 (1.0) 2.71 (1.1) 2.91 (0.8) 0.4(d)
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Baseline sleep quality P
Good (PSQI 0-3) Moderate (PSQI >3-5) Poor (PSQI >5)
Matched control 3.78 (1.0) 1.97 (1.1) 5.11 (1.3)
P=0.3(b) P=0.3(c)
Change from baseline 
QST measures
    Delta: trapezius 
pressure pain threshold 
(kPa)
Case −41.4 (17) −81.0 (17) −49.9 (13) 0.1(d)
Matched control 13.1 (15) 35.6 (18) 60.2 (21)
P<0.0001(b) P=0.3(c)
    Delta: Mean pinprick 
pain rating (0-100) 
(N=362)
Case 6.60 (2.9) 6.23 (3.0) 3.05 (2.2) 0.6(d)
Matched control −1.98 (2.6) −1.47 (2.9) −0.06 (3.6)
P=0.005(b) P=0.9(c)
    Delta: Pinprick post-
stimulus rating (0-100) 
(N=362)
Case 4.34 (1.2) 1.24 (1.3) 1.45 (0.9) 0.3(d)
Matched control −0.32 (1.1) 0.14 (1.3) −1.59 (1.5)
P=0.003(b) P=0.2(c)
(a)All mean estimates are adjusted for study site
(b)
P-value testing the null hypothesis of no statistically significant difference in baseline mean sleep quality between 
incident cases and matched controls (i.e. main effect)
(c)
P-value for testing the null hypothesis of no statistical significant difference between good, moderate and poor sleep 
quality (i.e. main effect)
(d)
P-value from the likelihood ratio test that assesses the statistical significance of the effect modification of the QST 
measures on the relationship between sleep quality and TMD case status (i.e. interaction)
Appendix Table 3
Association between subjective sleep quality and risk of first-onset TMD(a) among 2,410 
OPPERA prospective cohort study participants adjusted for baseline predictors of TMD; 
hazard ratios (95% confidence limits) (n=2,410)
Hazard Ratio (95% confidence limits)
Baseline PSQI score per 2.8 units 1.04 (0.90, 1.20)
Any non-pain facial symptom at baseline [ref=None] 1.74 (1.28, 2.38)*
Any comorbid health condition at baseline [ref=None] 1.64 (1.21, 2.21)*
Baseline PSS score per 6.4 units 1.16 (1.00, 1.35)
Baseline PILL score per 21.0 units 1.16 (1.01, 1.35)*
Time-varying covariate per 2.0 units 1.23 (1.07, 1.42)*
Model fit: likelihood ratio statistic (df) 135.2 (15)
(a)
The model adjusts for study site, age, sex and race/ethnicity
*
The symbol denotes a statistically significant predictor of first-onset TMD
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PERSPECTIVE
Subjective sleep quality deteriorates progressively prior to the onset of painful 
temporomandibular disorder (TMD), but sensitivity to experimental pain does not 
mediate this relationship. Furthermore, the relationship is independent of potential 
confounders such as psychological stress, somatic awareness, comorbid conditions, non-
pain facial symptoms and various demographic factors.
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Highlights
■ Subjective sleep quality worsened progressively prior to the onset of painful TMD.
■ Sleep quality was stable over time in participants who remained free of TMD.
■ Sleep quality was a stronger predictor of TMD than well-established TMD risk 
factors.
■ Worsening sleep quality did not predict an increase in pain sensitivity.
■ Pain sensitivity did not mediate the relationship between sleep quality and TMD.
Sanders et al. Page 19
J Pain. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig 1. 
In the nested case control study, sleep quality worsened over time in the lead-up to first-
onset TMD (n=220), but remained stable for matched controls (n=193). The four time 
periods on the horizontal axis refer to: the first quarter (i.e. 3 months) after enrollment; 
intermediate quarters fall between the first and penultimate quarters; the penultimate quarter 
immediately preceded the final quarter; and the final quarter (i.e. the 3 months prior to the 
follow-up visit at which presence or absence of TMD was determined). Estimates are 
adjusted means calculated from a generalized estimating equation regression model in which 
the numeric rating scale of sleep quality (range 0–10, higher scores denote worse sleep 
quality) was the dependent variable. Predictor variables were follow-up period (4 
categories), incident TMD case classification (2 categories) and their 2-way interaction. 
Error bars represent ± 1 standard error (se) of the adjusted mean. Estimates are adjusted for 
study site, sex, age in years and race/ethnicity.
The * symbol signifies a statistically significant difference (P <0.05) compared to the first 
quarter in the same study group.
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Table 1
Description of subjective sleep quality,(a) and rate of TMD incidence (% per annum, 95% confidence limits 
(CL)) for selected characteristics measured at baseline, OPPERA Prospective Cohort Study, 2006–2011 
(n=2,453).
N (%) in cohort PSQI mean (95%CL) Site-adjusted TMD incidence rate 
% per annum (95%CL)
All participants 2,453 (100.0) 4.6 (4.5, 4.7) 3.0 (2.7, 3.5)
Sex
    Male 982 (40.0) 4.6 (4.4, 4.8) 2.3 (1.8, 3.0)
    Female 1,471 (60.0) 4.6 (4.5, 4.8) 3.1 (2.6, 3.7)
Age (y)
    18-24 1,300 (53.0) 4.3 (4.2, 4.4) 2.2 (1.8, 2.8)
    24-34 666 (27.2) 4.7 (4.5, 4.9) 3.3 (2.6, 4.2)
    45-44 487 (19.9) 5.4 (5.1, 5.7) 3.4 (2.6, 4.6)
Race/ethnicity
    White 1,351 (55.1) 4.4 (4.3, 4.5) 2.7 (2.2, 3.3)
    African American 625 (25.5) 5.4 (5.2, 5.7) 3.6 (2.7, 4.7)
    Asian 239 (9.7) 4.2 (3.9, 4.5) 1.2 (0.6, 2.3)
    Hispanic 163 (6.6) 4.0 (3.6, 4.3) 2.4 (1.5, 4.1)
    Other 75 (3.1) 4.6 (3.9, 5.3) 2.8 (1.3, 5.8)
Pittsburgh Sleep Quality Index global score(b)
    0-5 1,725 (70.3) 2.1 (1.7, 2.5)
    >5 728 (29.7) 4.6 (3.8, 5.7)
Perceived Stress Scale
    Low tertile (≤11) 853 (34.9) 3.5 (3.3, 3.6) 2.0 (1.5, 2.6)
    Mid tertile (>11 to <17) 739 (30.3) 4.4 (4.3, 4.6) 2.4 (1.8, 3.1)
    High tertile (≥17) 850 (34.8) 6.0 (5.8, 6.2) 4.0 (3.3, 4.9)
Pennebaker Inventory of Limbic Languidness
    Low tertile (≤78) 857 (35.0) 3.6 (3.4, 3.7) 1.9 (1.5, 2.5)
    Mid tertile (79 to 94) 774 (31.6) 4.4 (4.3, 4.6) 2.0 (1.5, 2.7)
    High tertile (≥95) 820 (33.5) 5.9 (5.7, 6.1) 4.6 (3.8, 5.6)
Non-pain facial symptoms
    None 2,010 (82.1) 4.4 (4.3, 4.5) 2.3 (1.9, 1.9)
    1 or more 437 (17.9) 5.6 (5.3, 5.9) 5.2 (4.0, 4.0)
Count of 20 comorbidities
    None 1,571 (64.8) 4.1 (3.9, 4.2) 1.9 (1.6, 2.4)
    1 or more 854 (35.2) 5.6 (5.4, 5.8) 4.4 (3.6, 5.3)
Trapezius pressure pain threshold (kPa)
    Low tertile (≤281.5) 841 (34.6) 4.7 (4.5, 4.9) 3.1 (2.5, 4.0)
    Mid tertile (>281.5 to 450.0) 797 (32.8) 4.7 (4.5, 4.9) 2.8 (2.2, 3.6)
    High tertile (>450.0) 793 (32.6) 4.5 (4.3, 4.7) 2.2 (1.7, 2.9)
Mechanical cutaneous (pinprick) pain (0-100 rating)
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N (%) in cohort PSQI mean (95%CL) Site-adjusted TMD incidence rate 
% per annum (95%CL)
    Low tertile (≤5) 762 (32.0) 4.9 (4.6, 5.1) 3.0 (2.3, 3.8)
    Mid tertile (>5 to 20) 840 (35.2) 4.6 (4.4, 4.8) 2.5 (2.0, 3.3)
    High tertile (>20) 782 (32.8) 4.4 (4.2, 4.6) 2.6 (2.0, 3.4)
(a)Subgroup numbers for some characteristics may sum to less than 2,453 due to missing data for that characteristic
(b)
Pittsburgh Sleep Quality Index score in which higher scores denote worse sleep quality
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Table 2
Association between subjective sleep quality and risk of first-onset TMDa among 2,410 OPPERA prospective 
cohort study participants adjusted for baseline predictors of TMD; hazard ratios (95% confidence limits) 
(n=2,410)
Model 1: PSQI at 
baseline
Model 2: adds four 
covariates
Model 3: adds time-varying 
sleep quality
Baseline PSQI score >5 [ref=0-5] 2.04 (1.55, 2.70)* 1.39 (1.02, 1.90)* 1.28 (0.94, 1.75)
Any non-pain facial symptom at baseline 
[ref=None] 1.67 (1.22, 2.27)
* 1.69 (1.23, 2.30)*
Any comorbid health condition at baseline 
[ref=None] 1.65 (1.22, 2.23)
* 1.63 (1.20, 2.19)*
Baseline PSS score per 6.4 units 1.14 (0.98, 1.33) 1.14 (0.98, 1.32)
Baseline PILL score per 21.0 units 1.16 (1.01, 1.34)* 1.14 (0.99, 1.32)
Time-varying covariate of sleep quality rating >6 
[ref=0-6]: 1.73 (1.29, 2.32)
*
Model fit: likelihood ratio statistic (df) 78.1 (10) 123.0 (14) 137.8 (15)
aAll models are adjusted for study site, age, sex and race/ethnicity
*
The symbol denotes a statistically significant predictor of first-onset TMD
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Table 3
A mediation analysis showing hazard ratios (95%CI) for first-onset TMD comparing poor versus good 
baseline sleep quality, OPPERA prospective cohort study
Nested case control (N=431)
Model Baseline sleep quality Potential mediator Natural direct effect Natural indirect effect
1((a), (c)) PSQI ≤5 (ref) Baseline pressure pain threshold Ref. Ref.
PSQI >5 (poor quality) 1.91 (1.59, 2.29)* 1.00 (0.83, 1.19)
2(b) PSQI ≤5 (ref) Baseline pressure pain threshold Ref. Ref.
PSQI >5 1.41 (1.15, 1.74)* 1.00 (0.83, 1.19)
3(a) PSQI ≤5 (ref) Change in pressure pain threshold Ref. Ref.
PSQI >5 1.90 (1.59, 2.28)* 1.00 (0.84, 1.20)
4((b), (d)) PSQI ≤5 (ref) Change in pressure pain threshold Ref. Ref.
PSQI >5 1.42 (1.16, 1.74)* 0.99 (0.83, 1.19)
(a)
Models 1 and 3 are adjusted for study site, age, sex and race/ethnicity
(b)
Models 2 and 4 are adjusted for study site, age, sex, race/ethnicity, perceived stress (Perceived Stress Scale, continuous variable), somatic 
awareness (PILL score, continuous variable), comorbid conditions (≥1 vs. 0) and non-pain facial symptoms (≥1 vs. 0)
(c)
For models 1 and 2, the mediator was a binary measure of baseline pressure pain threshold (PPT), dichotomized at the lower tertile (≤273.25 vs. 
>273.35).
(d)
For models 3 and 4, the mediator was a binary measure of change from baseline PPT, dichotomized at the lower tertile (≤77.5 vs. >77.5).
*
The symbol denotes a statistically significant predictor of first-onset TMD
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